Trial · NCT03990649
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Mean 24-Hour Pain Intensity as Assessed by NPS Score to the End of Part A | Double-Blind Treatment Period - Part A: Placebo | -0.74 | Standard Deviation 1.614 | scores on scale | |
| Change From Baseline in Mean 24-Hour Pain Intensity as Assessed by NPS Score to the End of Part A | Double-Blind Treatment Period - Part A: Soticlestat | -1.05 | Standard Deviation 1.310 | scores on scale | |
| Percent Change From Baseline in Mean 24-Hour Pain Intensity as Assessed by NPS Score to the End of Part A | Double-Blind Treatment Period - Part A: Placebo | -12.20 | Standard Deviation 29.108 | percent change | |
| Percent Change From Baseline in Mean 24-Hour Pain Intensity as Assessed by NPS Score to the End of Part A | Double-Blind Treatment Period - Part A: Soticlestat | -18.35 | Standard Deviation 23.699 | percent change | |
| Percentage of Participants Considered Responders at the End of Part A | Double-Blind Treatment Period - Part A: Placebo | 22.2 | percentage of participants | ||
| Percentage of Participants Considered Responders at the End of Part A | Double-Blind Treatment Period - Part A: Soticlestat | 26.7 | percentage of participants | ||
| Change From Baseline in Domain Score of PROMIS-29 Version 2.1 at the End of Part A | Double-Blind Treatment Period - Part A: Placebo | Physical Function | 1.53 | Standard Deviation 2.207 | t-score |
| Change From Baseline in Domain Score of PROMIS-29 Version 2.1 at the End of Part A | Double-Blind Treatment Period - Part A: Soticlestat | Physical Function | 2.39 | Standard Deviation 4.042 | t-score |
| Change From Baseline in Domain Score of PROMIS-29 Version 2.1 at the End of Part A | Double-Blind Treatment Period - Part A: Placebo | Anxiety | 3.29 | Standard Deviation 10.348 | t-score |
| Change From Baseline in Domain Score of PROMIS-29 Version 2.1 at the End of Part A | Double-Blind Treatment Period - Part A: Soticlestat | Anxiety | -1.99 | Standard Deviation 9.567 | t-score |
| Change From Baseline in Domain Score of PROMIS-29 Version 2.1 at the End of Part A | Double-Blind Treatment Period - Part A: Placebo | Depression | 1.15 | Standard Deviation 10.011 | t-score |
| Change From Baseline in Domain Score of PROMIS-29 Version 2.1 at the End of Part A | Double-Blind Treatment Period - Part A: Soticlestat | Depression | -0.78 | Standard Deviation 6.902 | t-score |
| Change From Baseline in Domain Score of PROMIS-29 Version 2.1 at the End of Part A | Double-Blind Treatment Period - Part A: Placebo | Fatigue | 0.45 | Standard Deviation 12.126 | t-score |
| Change From Baseline in Domain Score of PROMIS-29 Version 2.1 at the End of Part A | Double-Blind Treatment Period - Part A: Soticlestat | Fatigue | -3.66 | Standard Deviation 10.456 | t-score |
| Change From Baseline in Domain Score of PROMIS-29 Version 2.1 at the End of Part A | Double-Blind Treatment Period - Part A: Placebo | Sleep Disturbance | 2.13 | Standard Deviation 5.110 | t-score |
| Change From Baseline in Domain Score of PROMIS-29 Version 2.1 at the End of Part A | Double-Blind Treatment Period - Part A: Soticlestat | Sleep Disturbance | 2.55 | Standard Deviation 1.927 | t-score |
| Change From Baseline in Domain Score of PROMIS-29 Version 2.1 at the End of Part A | Double-Blind Treatment Period - Part A: Placebo | Ability to Participate in Social Roles | 1.66 | Standard Deviation 6.051 | t-score |
| Change From Baseline in Domain Score of PROMIS-29 Version 2.1 at the End of Part A | Double-Blind Treatment Period - Part A: Soticlestat | Ability to Participate in Social Roles | 2.74 | Standard Deviation 5.147 | t-score |
| Change From Baseline in Domain Score of PROMIS-29 Version 2.1 at the End of Part A | Double-Blind Treatment Period - Part A: Placebo | Pain Interference | -1.53 | Standard Deviation 6.257 | t-score |
| Change From Baseline in Domain Score of PROMIS-29 Version 2.1 at the End of Part A | Double-Blind Treatment Period - Part A: Soticlestat | Pain Interference | -0.38 | Standard Deviation 7.597 | t-score |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03990649/results